Drugs / SUPINOXIN
SUPINOXIN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02003092 | Aug 2013 → Oct 2019 | triple-negative breast carcinoma | Rexahn Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SUPINOXIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL1278118 ↗ |
| Known as | P-p68 inhibitor rx-5902 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1278118 ↗ |
| Known as | RX-5902 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02003092 ↗ |
| Modality | Small molecule | — CHEMBL1278118 ↗ |
| Route | Oral | “RX-5902 will be administered orally daily for 3 weeks followed by 1 week of rest in each cycle.” NCT02003092 ↗ |